Daptomycin dosing based on ideal body weight versus actual body weight: Comparison of clinical outcomes

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 88-93

  Ng, Jennifer K ^a   Schulz, Lucas T ^a   Rose, Warren E ^b   Fox, Barry C ^c   Andes, David R ^c   Buhr, Kevin A ^b   Fish, Jeffrey T ^a  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACTUAL BODY WEIGHT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; EOSINOPHILIA; FEMALE; FOLLOW UP; HUMAN; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BODY WEIGHT; DAPTOMYCIN; ENTEROCOCCUS; FEMALE; HUMANS; IDEAL BODY WEIGHT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84891545533     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01018-13     Document Type: Article

References (15)

1. Dvorchik BH, Damphousse D. 2005. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J. Clin. Pharmacol. 45:48-56. http://dx.doi.org/10.1177/0091270004269562
2. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318- 1323. http://dx.doi.org/10.1128/AAC.47.4.1318-1323.2003
3. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68. http://dx.doi.org/10.1128/ AAC.48.1.63-68.2004
4. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. 2007. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 51: 2741-2747. http://dx.doi.org/10.1128/AAC.00059-07
5. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574. http://dx.doi.org/10.1086/652767
6. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. 2009. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin. Ther. 31:1936-1945. http://dx.doi.org/10.1016/j.clinthera. 2009.09.012
7. Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ. 2013. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy 33:3-10. http://dx.doi.org/10.1002/phar.1220
8. Murray KP, Zhao J, Davis SL, Kullar R, Kaye K, Lephart P, Rybak MJ. 2013. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin MIC >1 mg/liter: a matched cohort study. Clin. Infect. Dis. 56:1562-1569. http://dx.doi.org/10.1093/cid/ cit112
9. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. 2009. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219. http://dx.doi.org/10.1345/aph.1M085
10. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. 2010. High-dose daptomycin in documented Staphylococcus aureus infections. Int. J. Antimicrob. Agents 36:459-461. http://dx.doi.org/10.1016/j.ijantimicag.2010. 07.011
11. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. 2011. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536. http://dx.doi.org/10.1592/phco.31.6.527
12. Woodworth JR, Nyhart EH, Jr, Brier GL, Wolny JD, Black HR. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 36:318-325. http://dx.doi.org/10.1128/AAC.36.2.318
13. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06
14. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ. 2008. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int. J. Clin. Pract. 62:1455-1464. http://dx.doi.org/10.1111/j.1742-1241.2008.01854.x
15. Lodise TP, Jr, Lomaestro B, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended- infusion dosing strategy. Clin. Infect. Dis. 44:357-363. http://dx.doi.org/10. 1086/510590